- Conditions
- Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–47
of 23
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- ABT-957, Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Cypress, California • Orlando, Florida • The Villages, Florida + 6 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Florbetapir F 18 PET Scan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 77
- States / cities
- Anaheim, California • Imperial, California • Irvine, California + 59 more
- Conditions
- Alzheimer Disease
- Interventions
- ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
- Drug
- Lead sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- LY2599666, Solanezumab, Placebo SC, Placebo IV
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
- Conditions
- Alzheimer's Disease
- Interventions
- Photobiomodulation
- Device
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
- Interventions
- SAGE-718
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
- Conditions
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Leronlimab (700mg)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- high CBD/low THC sublingual solution
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- LY2886721, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 21 more
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease
- Interventions
- AGB101, Placebo
- Drug
- Lead sponsor
- AgeneBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Nicotinamide, Placebo Comparator
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Irvine, California • Los Angeles, California
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more
- Conditions
- Mild Cognitive Impairment, Dementia
- Interventions
- CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
- Drug
- Lead sponsor
- CuraSen Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Canakinumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Charlestown, Massachusetts • Stony Brook, New York
- Conditions
- Alzheimer Disease
- Interventions
- low intensity focused ultrasound (LIFU)
- Device
- Lead sponsor
- Ali Rezai
- Other
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Cognitive Dysfunction, Dementia, Mild
- Interventions
- FitMi AD, Conventional exercise program
- Device · Other
- Lead sponsor
- Flint Rehabilitation Devices, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Downey, California
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
- Interventions
- BIIB080, BIIB080-matching placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
- Interventions
- Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Biological
- Lead sponsor
- Steven E Arnold, MD
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease
- Interventions
- Placebo Oral Tablet, AGB101 220 mg tablet
- Drug
- Lead sponsor
- AgeneBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3002813-IV, LY3002813-SC, Placebo-IV
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Long Beach, California • Orlando, Florida • Atlanta, Georgia + 1 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3002813, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
- Conditions
- Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
- Drug
- Lead sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
- Federal
- Eligibility
- Not listed
- Enrollment
- 8,680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland